Nicholas Fidelman, Md

This phase 2 pilot study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with liver-directed treatments (like embolization or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink tumors in people with well-differentiated neuroendocrine tum…